1July 2000, Guangzhou Konzern Medicine Co., Ltd. ("Konzern Medicine") was privatized from state-owned enterprise and primarily engaged in pharmaceutical distribution in China.
June 2004, Konzern Medicine was recognized as high-tech private enterprise in Guangzhou.
In 2005, Lounsberry Holdings III, Inc. was established and registered in the state of Delaware, USA.
February 2006, Lounsberry Holdings III, Inc. acquired Konzern Medicine through reverse acquisition, went public and listed in Over-The-Counter Bulletin Board of NASDAQ.
May 2006, the Company changed its name from Lounsberry Holdings III, Inc. to China Medicine Corporation.
June 2006, Guangzhou Co-win Bioengineering Co., Ltd. ("Co-Win") was jointly founded by Konzern Medicine, Jinan University and Prof. Dongsheng Yao with 70% of shares owned by Konzern Medicine. Co-Win mainly focuses on the research and development of rADTZ project and will also undertake its commercialization.
June 2009, the Company re-domiciled in the State of Nevada, USA.
October 2009, Konzern Medicine acquired Guangzhou Lifetech Pharmaceutical Co., Ltd. (Lifetech Pharm) and Guangzhou Lifetech Technological Co., Ltd. (Lifetech Technology). Till such acquisition was closed in December 2009, the Company has gradually evolved to be a vertically integrated developer, manufacturer, and distributor of pharmaceutical industry.
December 2009, the Company entered into a $69.6 million financing with One Equity Partners ("OEP"), the global private equity investment arm of JPMorgan Chase & Co.. This deal was closed in February 2010.
January 2010, the Company submitted the application to establish a holding company, Konzern Company Limited, in China. In May, 2010, Konzern Company Limited changed its name to Konzern Group Ltd. ("Konzern Group") and the current structure of the Group was finalized.